AntibodystaleSun Yat-sen UniversityPhase 2
disitamab vedotin (Disitamab Vedotin, RC48, RC48+Tislelizumab+carboplatin)
Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer
#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE